FDA Drug · D-0539-2025

EVENITY, (romosozumab -aqqg) injection, 105mg/1.17 mL, For Subcutaneous Use Only, Rx Only, Manufactured by: Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-880-02.

Class II · Ongoing

CGMP Deviations; potential temperature excursions due to transit delays

Affected lots / codes — check yours against thisLot: 1178382, Expiration date: 3/31/2027

Recalling firm: Mckesson Medical-Surgical Inc. Corporate Office, Richmond, VA
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: 2 Pre-filled syringes
Distribution: Within the U.S - OH, VA, FL.
Recall initiated: April 21, 2025
Classified: July 21, 2025
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0539-2025%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

See every recall for this brand: Is EVENITY recalled? →

Check this brand across all 8 databases →